Hygea Medical Technology

Hygea Medical Technology (海杰亚医疗) is a Beijing-based medical device company focused on minimally invasive tumor interventional therapy and cryogenic medicine, founded in 2010 . It built a proprietary technology platform around its globally first-of-its-kind Kangbo Knife (康博刀), a composite cryoablation system that integrates deep-low-temperature freezing with high-intensity thermal therapy . The system has gone through multiple iterations, with the 3.5-generation Elf-S10 model launched in June 2024—44% smaller and 25% lighter than its predecessor—indicated for solid tumors including liver, lung, breast, kidney, pancreatic, and bone cancers .

The company has raised multiple rounds, including a Series C+ in 2021 led exclusively by Gaorong Ventures and a Series D in early 2023 led by IN Capital with follow-on from Gaorong . Beyond hardware, Hygea has expanded into AI-assisted imaging: in late 2024 it received Beijing's first approval for a Class II AI medical device software for liver CT image processing, designed to automate segmentation for pre-operative ablation planning . Its cryoablation systems have achieved leading market share in China with broad coverage in top-tier tertiary hospitals, though the company notes that advancing clinical acceptance requires extensive physician education and guideline inclusion .